Targeting Plasma Cells in Autoimmune Diseases
Antibodies specific for self-antigens mediate life-threatening pathology in several autoimmune diseases. Clearly the ability to target the plasma cells (PCs) producing the autoantibodies would be of great clinical benefit. Current immunosuppressive therapies are based on the premise that autoreactiv...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
The Rockefeller University Press
2004
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211780/ |
| id |
pubmed-2211780 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-22117802008-03-11 Targeting Plasma Cells in Autoimmune Diseases Tarlinton, David M. Hodgkin, Philip D. Commentary Antibodies specific for self-antigens mediate life-threatening pathology in several autoimmune diseases. Clearly the ability to target the plasma cells (PCs) producing the autoantibodies would be of great clinical benefit. Current immunosuppressive therapies are based on the premise that autoreactive PCs are short-lived and replenished from ongoing immune responses. However, recent results question this assumption and suggest that optimizing the treatment of severe autoimmune conditions will require a significant investment in elucidating the details of PC biology. The Rockefeller University Press 2004-06-07 /pmc/articles/PMC2211780/ /pubmed/15173204 http://dx.doi.org/10.1084/jem.20040719 Text en Copyright © 2004, The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/). |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Tarlinton, David M. Hodgkin, Philip D. |
| spellingShingle |
Tarlinton, David M. Hodgkin, Philip D. Targeting Plasma Cells in Autoimmune Diseases |
| author_facet |
Tarlinton, David M. Hodgkin, Philip D. |
| author_sort |
Tarlinton, David M. |
| title |
Targeting Plasma Cells in Autoimmune Diseases |
| title_short |
Targeting Plasma Cells in Autoimmune Diseases |
| title_full |
Targeting Plasma Cells in Autoimmune Diseases |
| title_fullStr |
Targeting Plasma Cells in Autoimmune Diseases |
| title_full_unstemmed |
Targeting Plasma Cells in Autoimmune Diseases |
| title_sort |
targeting plasma cells in autoimmune diseases |
| description |
Antibodies specific for self-antigens mediate life-threatening pathology in several autoimmune diseases. Clearly the ability to target the plasma cells (PCs) producing the autoantibodies would be of great clinical benefit. Current immunosuppressive therapies are based on the premise that autoreactive PCs are short-lived and replenished from ongoing immune responses. However, recent results question this assumption and suggest that optimizing the treatment of severe autoimmune conditions will require a significant investment in elucidating the details of PC biology. |
| publisher |
The Rockefeller University Press |
| publishDate |
2004 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211780/ |
| _version_ |
1611433845317435392 |